For example, genetically-proxied inhibition of HMGCR, which mimics the effect of statins, was found to be associated with a lower risk of CRC (OR = 0.69; 95%CI 0.49–0.99) in the study by Rodriguez-Broadbent et al. that involved a 6-SNPs genetic risk score and 9254 CRC cases [11], but not in the study by Carter et al. using the same 6-SNPs and 5486 cases from the UKB (1.05; 0.65-1.72 per SD decrease in LDL-C) [14]. The gene discussed is HMGCR; the disease is colorectal carcinoma.